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PHARMACOLOGY OF OPHTHALMOLOGICALLY IMPORTANT DRUGS
JAMES L . TUCKER, JR.,

M.D.

DRUG THERAPY IN ophthalmology, like many specialties in medicine, encompasses the
entire spectrum of pharmacology. This is true for any specialty that routinely involves
the care of young and old patients, surgical and non-surgical problems, local eye
disease (topical or subconjunctival drug administration), and systemic disease which
must be treated in order to "cure" the "local" manifestations which frequently
present in the eyes (uveitis, optic neurhis, etc.).
Few authors (see bibliography) have attempted an introduction to drug therapy
oriented specifically for the ophthalmologist. The new resident in ophthalmology
often has a vague concept of the importance of this subject, and with that in mind
this paper was prepared. Revisions have been made in the original text which may
allow this brief review of some important drugs to be of interest to other specialties.
The oudine followed is:
I. Drugs Related to the Autonomic
A.

Cholinergic

Nervous

System

Drugs

1. parasympathetic stimulants
2. parasympathetic depressants
B. Adrenergic

Drugs

1. sympathetic stimulants
2. adrenergic blocking agents (sympatholytic)
11. Mi.sceUaneous Drugs in

Ophthalmology

It is apparent that further sections could be written for antibiotics, topical
and systemic, steroids, topical and systemic, tranquilizers, anesthetics, etc. These
topics were not within the scope of this discussion.
Department of Ophthalmology
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I. Drugs Related to the Autonomic

Nervous

System

In general the sympathetic system corresponds to the adrenergic nervous system,
and the parasympathetic nervous system to the cholinergic system, i.e., the adrenergic
nerve endings act through the liberation of epinephrine and the chohnergic nerve
endings act through the liberation of acetylcholine. Parasympathetic, sympathetic,
mimetic and lytic are not particularly good terms for acetylcholine or epinephrine,
since these are the substances released at the autonomic synapses. Acetylcholine
also transmits impulses in all preganglionic synapses, both sympathetic and parasympathetic, in the myoneural junctions of the voluntary nervous system and probably
all synapses of the central nervous system. Acetylcholine is rapidly inactivated by
cholinesterase, and this action can be blocked by drugs with a urethane (carbamate)
group that combines with esterase, such as physostigmine or prostigmine.
An early theory was that adrenergic nerve endings acted through the liberation
of epinephrine which then combined with a substance to form sympathin which in
turn initiated the action of the innervated cell. There was thought to be two types
of sympathin produced, E and I — excitatory and inhibitory, for physiologists
could readily demonstrate opposite sympathetic actions when epinephrine was administered intravenously.
Ahlquist in 1948 made a thorough study of the effects of epinephrine and his
views are generally accepted today. He feels there are two types of receptors, alpha,
associated with excitatory responses and beta, associated with inhibitory responses.
Lands in 1952 added a third receptor, the undifferentiated, which he considers the
receptor in the heart and must also include an undifferentiated receptor in the
intestine, since it does not react in an alpha-beta pattern when adrenergic drugs
are administered.
The action of any cell with an adrenergic nerve supply can be initiated either
by stimulation of that particular nerve supply or by epinephrine reaching the nerve
cell through the general circulation. A number of epinephrine derivatives possess
qualitative actions somewhat similar to epinephrine but not exactly the same. Ephedrine
probably acts directly on adrenergic structures to a limited extent, but at least the
major portion of its effect is dependent on a cocaine-like action which is a sensitization
of the structure to epinephrine. Other epinephrine derivatives intermediate between
epinephrine and ephedrine with regards to the OH groups in the aromatic ring are
also intermediate in their pharmacologic mode of action.
Introductory

Definitions

1) Cholinergic Nerves — These include all nerves which release acetylcholine
at their terminals. Thus included are not only the postganglionic parasympathetic fibers, but also all autonomic preganglionic nerves (whether they
be parasympathetic or sympathetic).
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2)

Adrenergic Nerves — These are nerves that have impulses acting through
the release of norepinephrine or epinephrine and consist only of postganglionic
sympathetic fibers.

3)

Acetylcholine Esterase — This enzyme destroys acetylcholine by hydrolysis.

4)

Muscarine

yCHO
(CH3)3-N-CH
'^CH-0-H-CH2-CH3
This drug, vagal in action, acts identically to acetylcholine and pilocarpine
as a smooth muscle stimulant. Exocrine gland cells that are innervated by
postganglionic cholinergic nerves are also activated by muscarine. It produces
cardiac slowing and peripheral vasodilation.

It also produces

increased

peristalsis, depression of blood pressure, sahvation, bronchospasm, vasodilation, miosis, and sweating. Small doses of atropine completely abolish these
responses to muscarine.
5)

Nicotine — The major action of nicotine consists of a primary transient
stimulation and a secondary more persistent depression of all sympathetic
and parasympathetic ganglia.

Acetylcholine is also called nicotinic in its

actions on ganglia and skeletal muscles, since nicotine and acetylcholine can
allow transmission of nerve impulses across synapses in autonomic ganglia
and the transmission of impulses to skeletal muscles.
6)

There are probably other classes of nerve fibers such as those sensitive
to histamine, but very little is known of most of these responses and they
are not considered within the scope of this presentation.

AUTONOMIC INNERVATION OF THE EYE

The iris and ciliary body are innervated by the autonomic nervous system. The
sympathetic nerves are the postganglionic fibers from the cervical chain and these
reach the globe by the long ciliary nerves.

The parasympathetic supply traverses

the ciliary ganglion where there is a synapse and reaches the globe in the postganglionic
fiber by way of the short ciliary nerves.
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A. Cholinergic Drugs (These act on effector cells innervated by cholinergic
nerves.)
1. parasyinpathetic

stimulants

a. preganglionic (parasympathetic stimulatory miotics)
(1)

nicotine — direct action

(2)

acetylcholine — direct action

(3)

inethacholine chloride — (mecholyl chloride) — direct
action

(4)

carbachol — (Doryl) — direct and indirect action

(5)

urecholine — (bethanechol) — direct and indirect action

(6)

physostigmine — (Eserine) — indirect action

(7)

neostigmine — (prostigmin) — indirect action

(8)

DFP — (Floropryl) — indirect action

(9)

demecarium bromide — (Humorsol) — indirect action

(10)

echothiophate — (phospholine iodide) — indirect action

(1)

nicotine

The major actions of nicotine consist of a primary transient stimulation of all
sympathetic and parasympathetic ganglia and a secondary more persistent depression
of all sympathetic and parasympathetic ganglia. During the stage of excitation preganglionic nerve impulses are more effective, and during the stage of complete
paralysis such impulses are wholly ineffective. Nicotine does not interfere with the
release of acetylcholine in the ganglia by cholinergic preganglionic impulses, but it
renders the ganglion cells temporarily more sensitive and then more resistant to
acetylcholine. Both the initial excitation and the subsequent paralysis are due to a
direct action on the ganglion cells. Nicotine and curare are similar in their impulse
blocking, but nicotine much more in ganglia, and curare much more in skeletal
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muscles. The expression "nicotinic action" in referring to the action of the chohne
esters on autonomic ganglia, adrenal medulla, and skeletal muscles arises from the
similarity between the effects of nicotine and acetylcholine on these structures.

(2)

acetylcholine

(CH3)3-N-CH2-CH2-0-C-0-CH3
O
H
Like other quarternary ammonium compounds acetylcholine possesses three
distinct pharmacological effects; namely, muscarinic, nicotinic, and curariform.
Acetylcholine is actually preganglionic and postganglionic in its action. It acts
directly on the sphincter muscle in the eye which is the effector organ.
Cells reacting to acetylcholine fall into two distinct categories
whether they are innervated by:

according to

(1) preganglionic cholinergic nerves: nicotinic actions, i.e., somatic autonomic
ganglion cells, adrenal medullary cells, and skeletal muscle fibers. (The pharmacology
of the autonomic ganglionic synapse bears many resemblances to that of the skeletal
muscle end-plate).
(2) postganglionic cholinergic nerves, muscainic action, i.e., cardiac muscles,
smooth muscle cells (iris) and exocrine gland eel's.
Acetylcholine is not official and is not described in the New and Nonofficial
Remedies (N.N.R.) but can be obtained as the chloride or the bromide, which is
a white odorless powder, hygroscopic and readily destroyed by heat. The chloride
powder is packaged as 100 milligrams in an air-tight vial prepared by Merck and
Company, Rahway, New Jersey; the Chemical Division.
Applied locally to the eye acetylcholine is not effective, i.e., it is not a miotic
unless a 5% solution is used and massage is employed. It is most frequently used
for miosis applied directly to the iris during surgery to obtain rapid miosis in spite
of a retrobulbar nerve block. It is prepared by placing I cc. of normal saline in the
vial of 100 milligrams and withdrawing 0.1 cc. of the solution. This 10 mg mixed
with 9.9 cc. of normal saline, producing a dilution of 1:100, a concentration of one
milligram per cc. Three to five cc. of this solution are used for maximum miosis.
Acetylcholine is unstable in solution and must be prepared immediately before use.
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(3)

methacholine chloride — (mecholyl, acetylbetamethylcholine
chloride), a synthetic substituted acetylcholine.

CH3C—O—CH—CH2N-(CH3)3CI
CH3
Mecholyl is much more resistant to destruction by cholinesterase than is acetylcholine but it is still a short-acting drug.
Methacholine is a white crystalline or powdered chemical, deliquescent, fairly
stable in aqueous solution if slightly acid.
Methacholine is used in 10-20% solutions (less than 5% has no effect) and like
other choline derivatives penetrates corneal epithelium poorly. Absorption is enhanced
by using a topical anesthetic first. (This tends to damage the epitheUal cells enough
to lower the surface tension). When applied to the conjunctival sac, it retains its
maximal effect less than one hour and all effects are gone in several hours. Used
in normal eyes, the intraocular pressure will fall 3-5 mm. Hg.
It is used with neostigmine or physostigmine so their anticholinesterase effect
will allow the mecholyl to act without enzyme interference. It is used (but infrequendy)
to treat acute angle closure glaucoma, relieving the congestive attack. Mecholyl is
also a vasodilator which increases the permeability of the blood-aqueous barrier
but is rarely used for long-term administration. The drug is contraindicated in asthmatics, because of the possibility of bronchospasm. Reactions are not infrequent and
include sweating, flushing, an increase in pulse rate and a fall in blood pressure.
(4)

carbachol (doryl, lentin, carcholin, carbamyl chloride)

Cl • ( C H 3 ) 3 — N — C H 2 — C H 2 — O — C O — N H o

Carbachol is a powerful synthetic parasympathomimetic drug, used in the therapy
of chronic simple glaucoma. It acts preganglionically and postganglionically with a
stimulatory effect. Carbachol not only has an acetylcholine-like action on the motor
end plate, but also an inhibiting effect on cholinesterase. It is a derivative of choline
and is not susceptible to destruction by cholinesterase.
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Therefore, it is not enhanced nor prolonged in action by neostigmine or physostigmine which inactivate cholinesterase. This miotic may produce iris border cysts as
do several other miotics, but these are not a permanent deterrent to vision. It is a
urethane ester of choline and is more stable than methacholine. It is prepared as a
% % - 11/2% - 3% solution, and the brand available in our pharmacy is Isopto
Carbachol by Alcon Laboratories. It is supplied in 15 cc. plastic bottles and administered one or two drops in each eye every four to eight hours. It is somewhat
stronger than pilocarpine, but unfortunately does not penetrate the cornea as well.
It is enhanced in its penetration by the use of a petrolatum base or with a wetting
solution such as benzalkonium chloride 1:5000. Carbachol is a good replacement or
alternate drug for piloca.rpine or other miotics when resistance or intolerance has
developed. This often permits carrying the patient along under control with later
possibilities of returning to the original medication.
(5)

urecholine (bethanechol, carbamylmethylcholine chloride)

CI • (C H 3) 3 — N — C H 2 - C H - ( C H 3 ) - 0 - C O—N H o

H
V

H /

Urecholine is prepared as a 1% solution and is approximately equal to 2%
pilocarpine and .75% carbachol in its miotic effect in the treatment of chronic simple
glaucoma. Both carbachol and urecholine should be used with caution in asthmatics
where spasm of the bronchial musculature may occur. It is noted that these two
drugs have both preganglionic and postganglionic actions. Urecholine, like carbachol,
has direct and indirect action as a stimulant miotic acting on the motor end plate
as does acetylcholine, and it inhibits cholinesterase.
(6)

H

physostigmine (Eserine)

CH3
N

CM.
CH2

OH
/
C6
AH
"4
\

CH3 CH3
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This is an alkaloid obtained from the Calabar bean (ordeal bean) which is the
dried ripe seed of Physostigma venenosum Balfour, a perennial woody climber growing
on banks of streams in tropical West Africa. It was brought to England in 1840
but not really investigated until 1855. The first therapeutic use was by Laqueur in
1875 for glaucoma. Although several alkaloids have been isolated from the Calabar
bean, physostigmine (Eserine) is the most important. Physostigmine salts and their
aqueous solutions in glass containers oxidize upon exposure to air and light and
turn at first pink and then reddish brown. Such colored solutions are decomposed
and should not be used. Addition of boric acid to the solution prevents this breakdown. Eserine acts primarily as a cholinesterase inhibitor and will not affect an
iris which has been cholinergically denervated. (Loss of cholinergic innervation to
the iris results in the absence of formation of acetylcholine.) Therefore, Eserine
administered in the presence of a retrobulbar block is not effective until the retrobulbar
anesthesia has worn off. By preventing the rapid enzymatic hydrolysis of acetylcholine,
Eserine allows the acetylcholine to exert its characteristic actions in an intensified
manner. Unlike neostigmine, Eserine shows no component of direct action on skeletal
muscle. Eserine is most often used in ophthalmology for miosis in the therapy of
chronic simple glaucoma. The drug is well tolerated, stable and effective, all features
that enhance its popularity.
Atropine blocks the muscarinic effects of Eserine and curare prevents the nicotinic
effects on skeletal muscle and nicotine prevents the nicotinic effects on the autonomic
ganglia. Although many drugs inhibit cholinesterase, few compare with Eserine and
DFP and their related compounds for the potency of their inhibition. Physostigmine
does not destroy the enzyme as does DFP, but inactivates it temporarily by the
formation of a readily dissociable complex.
Symptoms and signs of Eserine toxicity include defecation, increased peristalsis,
miosis, salivation, dysarthria, nausea, vomiting, colic, fasciculatory twitchings all over
the body, nystagmus, restlessness, weakness, distant objects are blurred (spasm of
accommodation), lacrimation, sweating, copious bronchial secretions, dyspnea, urinary
urgency, ashen skin, weak pulse and blood pressure at shock levels. Death is by
pulmonary edema or central respiratory depression.
For ophthalmological use, Alcon Laboratories (Fort Worth, Texas) prepare
Isopto Eserine, a sterile 0.25% solution of eserine salicylate in .5%i methylcellulose.
As a preservative . 1 % sodium bisulfite and chlorobutanol 0.15% are also present.
Inactive ingredients include citric acid and sodium chloride. When applied to the eye,
miosis occurs in a few minutes and is maximal in 30 minutes. The effect persists
for 12-36 hours.
Eserine Ophthalmic Ointment is prepared for use in the eye as 0.25% eserine
sulfate and contains wool fat, light liquid petrolatum, and white petrolatum (DayBaldwin, Incorporated, Irvington, New Jersey).
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(7) rieostigmine (prostigmin)

N (CH3)3- SO4-CH3'

0-C-N-(CH3)2
Neostigmine is a synthetic substitute for physostigmine. It is available as the
methylsulfate and is prepared as a 5% ophthalmic solution. Systemically administered
neostigmine is without significant effect on the eye. Locally it produces miosis, but
not in the parasympathetically denervated iris. Neostigmine is a potent cholinesterase
inhibitor and its muscarinic properties are dependent upon an intact cholinergic
nervous system (as with physostigmine). Neostigmine exerts less potency on the
iris than does Eserine. Similar to acetylcholine, neosdgmine in small doses stimulates,
and in large doses depresses the autonomic ganglia and skeletal muscles. The muscarinic
effects of neostigmine are decreased or blocked with atropine and the nicotinic
effects by curare. Neostigmine finds its primary uses in the treatment of intestinal
ileus, atony of the bladder and myasthenia gravis.
(8) DFP (Di-isopropyl Fluorophosphate, AlkyI Fluorophosphate,
Isofluorophosphate, and Isoflurophate)

HC-O-P-O-CH
CH,

CH'

This drug is marketed by Merck, Sharp and Dohme, under the trade name of
Floropryl. Its pharmacological action is secondary to its inactivation of cholinesterase.
The inactivation of cholinesterase by DFP is irreversible, which is in contrast
to physostigmine and neostigmine, although all these drugs have similar nicotinic
and muscarinic actions. DFP is the most potent and persistent miotic known and its
usefulness in the therapy of chronic simple glaucoma is limited primarily because
there are effective drugs which are less expensive and more stable in solution.
DFP hydrolyzes in the presence of water and hence must not be diluted or it
rapidly decomposes (even moisture on eyelids must be excluded from the drug when
199

_

TUCKER
applying i t ) . It is prepared in a sterile . 1 % solution in anhydrous peanut oil, and
as a .25% ointment. It is marketed only for ophthalmological use and the usual
dosage is one drop in each eye for an adult every 12-72 hours, or one-fourth inch
of the ointment every 12-72 hours in children. If it is used too frequentiy or for
too prolonged a period of time, particularly in children, a high percentage of the
eyes form iris cysts. These usually disappear on cessation of the drug. Used in the
eye, there is a minimal systemic absorption. However, that the drug is absorbed
systemically is fact, evidenced by a slight fall in the serum cholinesterase. But
systemic effects rarely, if ever, occur when therapeutic concentrations are employed.
Occasionally, the intraocular tension is raised instead of lowered, especially in
narrow angle glaucoma, or in open angle glaucoma with narrow angles. This may
be due to an increase in the relative pupilary black and/or congestion of the iris
root. This drug should not be used when the chamber angle is narrow. Pericorneal
injection and congestive iritis sometimes occur early, but tend to disappear on
continued use of the drug. If the tension does not fall in 48 hours, one should
discontinue DFP and seek other measures for the control of the intraocular pressure.
The most common side effects are brow ache, blurred vision from ciliary spasm,
headache or photophobia — and in 20% of the patients one or more of these
symptoms force the discontinuence of the drug. Local irritation is uncommon.
Toxic symptoms include restlessness, weakness, skeletal muscular twitching,
tremor, ataxia, pilomotor erection, salivation, defecation, diarrhea, bradycardia, convulsions, respiratory depression, and death from respiratory depression and vascular
collapse.
Retinal detachment has occurred (rarely) irrespective of the amount of myopia
present. Allergy to peanut oil has been reported, and in these cases one can use
the ointment instead. Muscle twitching of the eyelids has been reported which is
due to a locally increased muscle tonus. DFP is also used in treating accommodative
esotropia. It reduces the centrally stimulated accommodation and its associated convergence by producing peripherally stimulated accommodation.
DFP can also be used as a diagnostic aid in evaluating strabismus to rule out
the possibility of an accommodative element.
It is contraindicated in the patient with vasomotor instability, peptic ulcer,
spastic G I symptoms, parkinsonism, bradycardia, asthma, recent myocardial infarction,
or epilepsy.
The antidote for accidental poisoning in the adult is .4 to .6 milligram of
atropine intramuscularly, and this may have to be repeated in order to reverse the
toxic effects.
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demecarium bromide (Humorsol, BC-48, Tosmilen)

N

CH-;

2 Br

Marketed by Merck, Sharp and Dohme, this drug is a synthetic cholinesterase
inhibitor. Humorsol is packaged for ophthalmological use only and is prepared as
a 0.25% sterile aqueous solution. It is stable at room temperature, is relatively
non-irritating, has a pH of 5-7, and when mixed with conjunctival fluid is isotonic.
Recently MSD has made available .125% Humorsol.
Pharmacologically, it is a quaternary ammonium compound whose generic name
is [decamethylenebis-(m-dimethylaminophenyl-N-methylcarbamate) dimethobromide].
In the structural formula, two neostigmine molecules are linked by a polymethylene
chain.
Humorsol applied locally to the conjunctival sac appears to produce as prolonged
inhibition of cholinesterase as DFP. (Both drugs marketed by MSD.) Its use in
the therapy of glaucoma and strabismus parallels that of DFP.
The increase in acetylcholine that accumulates produces miosis with spasm of
accommodation. This drug may produce hyperemia of the conjunctival vessels,
increased capillary permeability in the ciliary body and increased permeability of the
blood-aqueous barrier.
Humorsol is synergistic with several cholinesterase inhibitors. Prolonged side
effects occur from systemic ingestion (parasympathetic stimulator). Toxic symptoms
include nausea, vomiting, frequent urination, intestinal cramps, diarrhea, lacrimation,
bronchoconstriction, shock and collapse. Humorsol is used exclusively in the conjunctival sac. Instillation of the 0.25% solution ranges from one or two drops once
or twice a week to twice a day. It comes as a 5 cc. vial with a standardized
dropper. The dosage is individual, and the drug should be reduced to an absolute
minimum in order to avoid the formation of iris cysts.
Humorsol is used most often in the treatment of open angle glaucoma, for
breaking of peripheral anterior synechias, and in accommodative esotropia. As with
DFP, it should not be used in the presence of narrow chamber angles for fear of
precipitating an attack of angle closure glaucoma. In accommodative esotropia it
reduces centrally stimulated accommodation and its associated convergence by producing
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a peripherally stimulated accommodation. Humorsol may be used as a diagnostic aid
in determining if an esotropia has an accommodative element present.
The person administering Humorsol should be cautioned against overdosage, and
should press on the lacrimal canaliculi for a minute or two after instilling a drop
to prevent loss to the nasopharynx with subsequent systemic absorption from the
nasal mucosa. (This is a technique that should be employed with all eye medications
since it increases the length of time the eye is in contact with a drug.)
Early disagreeable symptoms, which usually disappear with continued use include
headache, browache, congestion of the sclera and conjunctival vessels, photophobia,
burning, induced myopia (blurred vision) and iridocyclitis. Comphcations that have
arisen with the use of Humorsol include ciliary spasm — so severe as to produce
retinal detachment, elevation of intraocular pressure instead of a lowering of the
intraocular pressure, muscle twitching of the eyelids .secondary to an increased tonus
of the skeletal muscles locally. Again, this drug is contraindicated in persons with
vasomotor instability, peptic ulcer, spastic G I symptoms, parkinsonism, bradycardia,
asthma, recent myocardial infarction, and epilepsy.
As in DFP, the antidote for toxic symptoms is .4 to .6 milligram of atropine
administered intramuscularly.
(10) echothiophate (phospholine iodide)

C2H5

o
(CH3)3-N-CH2-CH2-S—P=0-1

C2H5
Pharmacologically, diethoxyphosphinylthiocholine iodine is a potent and relatively
irreversible inhibitor of cholinesterase used only in ophthalmology.
Phospholine iodine is a white crystalline solid. (Campbell Pharmaceuticals, Incorporated, 121 East 24th Street, New York 10, New York.) It is prepared in a
5 cc. vials of 0.06%, 0.125% and 0.25% concentration which is administered one
drop every 12 to 48 hours and finds its greatest use in the treatment of open angle
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glaucoma. Also contained in the sterile solution is 1.2% mannitol, .5% chlorobutanol,
boric acid .06%, and disodium phosphate .026%. It has much the same action as
DFP, but is water soluble and more stable. However, it should be refrigerated when
in solution. The solution is stable for one month at room temperature but for about
12 months in the refrigerator.
It induces miosis in about 30 minutes which will last from several days to
three weeks. It improves outflow facility and lowers pressure in both normal and
most glaucomatous eyes. Fortunately, this drug is capable of lowering intraocular
pressure by improving outflow facility in some glaucomatous eyes which are not
controlled by other miotics and cholinesterase inhibitors. In many instances, Diamox
and/or topical epinephrine compounds can be discontinued. Phospholine iodine may
be used for diagnosis and/or therapy in accommodative esotropia. (See the similar
section under DFP and Humorsol.)
Side effects of phospholine iodine include browache, dimness of vision, and ciliary
and conjunctival injection which occur frequently when phospholine iodine is started,
but usually disappear after a few days of continued treatment. Aphakic eyes may
tolerate echothiophate better than phakic eyes. Rarely, retinal detachments have
been reported with the use of the drug. Iris cysts occur only occasionally in adults
but are fairly frequent in children. Phospholine iodine may activate or produce an
iritis and slit-lamp evaluation at frequent intervals for one week is recommended.
Care should be used when a patient is receiving anticholinesterase drugs. The
antidote is atropine 2 mgm. parenterally and artificial respiration if necessary if
accidental overdosage is encountered.
b. postganglionic

(parasympathetic
(1)

C2H5

CM

CH

CH2

stimulatory

miotics)

pilocarpine

C

N

CH

CH

CH
H N O 3 or HCl

0 = C

CHo
O

N

Pilocarpine is the chief alkaloid obtained from the leaflets of the South American
shrub known as Pilocarpus jaborandi and Pilocarpus microphilus. It was isolated
by Hardy in 1871.
The autonomic activity of the drug is due to a highly selective action of pilocarpine
on the cells innervated by postganglionic cholinergic nerves. This action is a direct
one on the reactive substance and also occurs after complete nerve degeneration.
Because of its effective miosis and infrequent idiosyncrasies it is a valuable drug in
the therapy of chronic simple glaucoma, either alone or in combination with other drugs.
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Atropine is the pharmacological antagonist to pilocarpine and prevents or counteracts all autonomic response to pilocarpine in the rather constant ratio of 1 to 10.
Particularly responsive to pilocarpine are the sweat and salivary glands. It is
interesting that dependent as ophthalmologists are on pilocarpine, Goodman and
Gilman's pharmacology text is quoted "the alkaloid (pilocarpine) has few clinical
uses and is perphaps not indispensable in medicine".
Isopto Carpine is pilocarpine hydrochloride (Alcon) in a sterile 0.5% methylcellulose suspension with benzalkonium chloride 1:25,000 and phenylmercuric nitrate
1:75,000 as preservatives. It also contains for isotonicity boric acid and sodium
citrate. The dosage for easily controlled open angle glaucoma is one drop in both
eyes four times a day of the selected strength which most readily controls intraocular
pressure in a given patient. This is determined by using the weakest dilution and
increasing the strength and/or the frequency of pilocarpine until the pressure is
controlled. Isopto Carpine is prepared in V2%, 1%, 2%, 3%, 4%, and 6% solutions.
A newer preparation* of pilocarpine H C l on the market is Pilocar, marketed by
Smith, Miller and Patch, Incorporated of New York.
Allergan Pharmaceuticals markets P. V. Carpine which is pilocarpine nitrate
in a polyvinyl alcohol (liquifilm) vehicle.
The following drugs have been discussed under preganglionic drugs, and it is
pointed out that they are classified as preganglionic drugs, and po^rganglionic since
4-10 act indirectly by allowing acetylcholine to accumulate.
(2)

acetylcholine

(3)

methacholine — mecholyl

(4)

carbachol — Doryl

(5)

urecholine — bethanechol

(6)

physostigmine — Eserine

(7)

neostigmine — prostigmin

(8)

DFP — Floropryl

(9)

demecarium bromide — Humorsol

(10)

echothiophate — phospholine iodide

2. Parasympathetic Blocking Agents — (parasympatholytic or depressor drugs)
a. preganglionic parasympathetic depressants — nicotine and curare are included
in this discussion because standard texts compare the action of many pharmaceuticals to the action of these drugs
(1)

nicotine

*Other pilocarpines include: Pilomiotin by Crookes Barnes Laboratory, Buf Opto Pilocel by
Professional Pharmaceutical Company, and Almocarpine by Ayerst Laboratories (Ophthalmos
Division). This example illustrates the large number of ophthalmological preparations available
from many different drug companies.
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The secondary action of nicotine is a more persistent depression of all sympathetic
and parasympathetic ganglia. See remarks under 1. parasympathetic stimulants, for
the formula and general pharmacology of nicotine.
(2)

curare

Curare is a generic term for various South American arrow poisons (alkaloids),
the first of which were derived from the plant Chondrodendron tomentosum.
Tubocurarine chloride

,OCH3

HO.

5H2O

The pharmacological actions include paralysis of the skeletal muscle fiber by
preventing its response to motor nerve impulses, i.e., to the acetylcholine liberated
by such impulses. It probably acts on the motor end plate raising its threshold to
acetylcholine. Curare, a quaternary ammonium compound, blocks autonomic ganglia
and has an initial excitatory phase much as nicotine and differs from hexamethonium
which is purely depressant. The main effects of curare are a highly selective paralysis
of the motor end plates in skeletal muscles and a paralysis of ganghon cells of the
autonomic nervous system. Thus, it blocks the nicotinic action of acetylcholine.
b. postganglionic parasympathetic depressants
(1)

H2C—c

atropine (tropinyl tropate)

CH2OH

CH2

HNCH3 CH — O
HoC'

-CH

C

O

C—C
H

CH2

Atropine is one of the naturally occurring alkaloids which inhibit the effector
organs innervated by the postganglionic cholinergic nerves. There are several other
alkaloids of the belladonna plants which do the same, but by far atropine and
scopolamine are the two most important clinically. Belladonna drugs are widely
distributed in nature, especially in the deadly nightshade, Atropa belladonna (contains
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mainly the alkaloids atropine and hyoscyamine). The same two alkaloids are also
found in jimson-weed, stink-weed, thornapple and devil's apple. The alkaloid, scopolamine (hyoscine) is found chiefly in the shrub Hyoscyamus niger, (henbane) and
Scopolia carniolica. These alkaloids are organic esters formed by the combination of
an aromatic acid, tropic acid, and complex organic bases either tropine (Tropanol)
or scopin. Scopin differs from tropine only in having an oxygen bridge between
the carbon atoms designated 6 and 7 in the structural formulas.
Atropine is the most useful drug available when complete cycloplegia, particularly
for prolonged periods, (postoperative cataract surgery or iritis) is desired. Cycloplegia
persists 8-12 days; mydriasis persists 7-10 days.
Isopto Atropine, a 1% sterile solution in .5%' methylcellulose, is atropine sulfate
(Alcon Laboratories, Fort Worth, Texas). For preservatives, it contains chlorobutanol
.15% and it is buffered with boric acid in distilled water. Our department uses
atropine ointment (Eli Lilly of Indianapolis) as the sulfate in a Vs ounce tube,
Vi % or 1 % concentration. This ointment contains anhydrous lanoHn, liquid petrolatum, white petrolatum, and purified water. Cycloplegic examination of children
younger than 5 years of age is often accomplished by having the V2 % ointment
instilled in their eyes three times a day for 3 days prior to the examination.
Ocular effects are obtained after local or systemic administration of the alkaloids,
but contrary to common opinion, the conventional dose of 0.6 mgm. of atropine
injected intramusculariy causes minimal ocular effect. However, scopolamine in equal
dosage causes definite mydriasis and a decrease in accommodative power. The
significance of this is reflected when preoperatively medicated patients with shallow
anterior chambers must be watched lest one precipitates an attack of acute angle
closure glaucoma.
The site of action of atropine is purely peripheral. The fatal dose of atropine
is probably higher than a usually recorded 100 milligrams for adults and 10 milligrams
for children. One drop of 1 % atropine solution contains approximately 0.5 milligrams
of atropine. Thus, the absorption of two drops has caused systemic atropine poisoning.
Atropine acts by preventing the effects of choline compounds, pilocarpine, and
muscarine on structures innervated by cholinergic nerves. However, atropine neither
destroys these compounds nor renders the innervated structure unresponsive to electrical
stimulation.
Atropine does not prevent the effect of choline derivatives on the autonomic
ganglion, the voluntary myoneural junction, or the central nervous system.
An interesting fact is that atropine will not dilate the pupil of a bird since the
avian iris sphincter is striated muscle and, therefore, is paralyzed not by atropine
but by curare.
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(2) scopolamine (6,7-epoxytropinyl tropate)

Scopolamine is stated to be more toxic than atropine, although this is not well
documented. Idiosyncrasies are more common with scopolamine than atropine. According to Goodman and Oilman, deaths from either scopolamine or atropine drops
are exceedingly rare. Allergic reactions, local or systemic, are not infrequent.
The ocular effects of V2 % (twice the concentration ordinarily used) scopolamine
are mydriasis in 20 to 30 minutes which lasts 3 to 5 days and cycloplegia which
occurs in one-half to one hour and lasts 5 to 7 days. This compares rather closely
with 1% atropine sulfate which produces a mydriasis in 30 to 40 minutes that la.sts
7 to 10 days and cycloplegia which has its onset in one to three hours and lasts 8
to 12 days. Like atropine, scopolamine acts by rendering tissues insensidve to
acetylcholine.
Scopolamine is used in our department as Isopto Hyoscine, 0.25% scopolamine
hydrobromide. It is in a sterile solution of .5% methylcellulose USP with .15%
chlorobutanol as a preservative. (Alcon Laboratories of Fort Worth, Texas.)
The main danger in the use of the belladonna alkaloids for cycloplegia and
mydriasis is an increase in intraocular pressure in persons with narrow angles. The
belladonna alkaloids are most useful in cycloplegic refractions, cycloplegia for relief
of ciliary spasm following corneal abrasions and postoperative intraocular surgery,
as well as for the relief of ciliary spasm in uveitis.

HoG

CH

(3)

synthetic belladonna .substitutes

(a)

homatropine (tropyl mandelate)

CH-

This is a synthetic drug which differs from atropine by having mandelic acid
substituted for the more complex tropic acid. It is both less effective and less toxic
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than atropine, and has a parasympatholytic potency of about one-tenth that of
atropine (approximately 1/50 as toxic as atropine).
Homatropine mydriasis either as the hydrobromide or hydrochloride in a 5%
solution has the advantage of rapid onset and relatively brief duration. The drug is
preferable to atropine when an extended period of increased intraocular pressure
must be avoided and when prolonged ocular effects are not necessary.
Maximum mydriasis is within 40-60 minutes and persists 1-2 days. Cycloplegia
is present within one hour. Accommodation is usually normal within 1-2 days
and homatropine is ineffective as a rule for the production of complete cycloplegia
in children younger than 5 years.
Isopto Homatropine 5% (Alcon Laboratories of Fort Worth, Texas) is a sterile
ophthalmic solution of the hydrobromide in .5% methylcellulose and distilled water.
It contains chlorobutanol .15% as a preservative and the inactive ingredients include
sodium phosphate dibasic and sodium phosphate monobasic. The dosage for routine
cycloplegia is usually one drop in each eye every 5 minutes for 3 doses. Homatropine
cycloplegia is used most frequently in the ages 7 to 15 years.
(b)

cyclogyl (cyclopentolate hydrochloride)

OH
^
C

CH3

C—O—CH2—CH2

N

• HCl
CH3

<y

More accurately cyclogyl is 2 dimethylamino-ethyl-l-hydroxy-alpha-phenylcyclo-

pentaneacetate hydrochloride.
In general, the usefulness of cyclogyl parallels that of homatropine:
1. Rapid onset of effect-cycloplegia usually is present within 30
to 60 minutes.
2. Effect is localized and specific.
3. Satisfactory in its response in persons with darkly pigmented
irises.
4. Uniform activity in a stable product.
5. Rapid decline of effect.
6. Low sensitivity and minimal intolerance reactions.
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Cyclogyl for ophthalmic instilladon (cycloplegic and mydriatic) is a sterile, clear
solution of .5%, 1% and 2% strengths in Gifford's buffer. Gifford's buffer contains
boric acid, potassium chloride, sodium carbonate monophosphate. Cyclogyl is manufactured by Schieffelin & Company, Pharmaceutical Laboratories Division, 28 Cooper
Square, New York 3, New York. The .5% and 1% cyclogyl contains benzalkonium
chloride as a preservative. The 2% cyclogyl is in a buffered ba.se containing boric
acid and sodium borate as well as polyvinylpyrrolidine (P.V.P.). The 2% cycloeyl
has 0.5% chlorobutanol as a preservative. Cyclogyl is used for relaxing the cholinergically innervated muscles in the iris and ciliary body for refraction, for intraocular
inflammatory reactions, keratitis, and for preventing or freeing existing synechia.
Although complete recovery occurs in 24 hours, one or two drops of 2% pilocarpine
reduces the recovery time to 6 hours or less. Caution should be exercised with
this drug in cases where there is increased intraocular tension or where there is a
shallow anterior chamber. In rare instances, atropine-like symptoms have been reported
with the 2% solution in young children.

(c)

euphthalmine (eucatropine hydrochloride)

OH

CH

CH-—C

-O

O

Cl

CH3

CH3

Euphthalmine is a synthetic mandelic acid ester useful as a mydriatic in older
patients. It is less active as a mydriatic than homatropine, and produces little
cycloplegic effect. It is prepared in a 5-10% solution and presently is most often
used in combination with phenylephrine in Mydriatin (Ayerst-Ophthalmos Division).
(d)

mydriacyl (bis-tropamide)

Mydriacyl (also tropicamide) is a synthetic drug, chemically defined as [tropic
acid-N-ethyl-N-(gamma-picolyl) amide], (Alcon Laboratories of Fort Worth, Texas).
It is a sterile isotonic soludon containing boric acid 1.8% and phenylmercuric nitrate
1:50,000 as a preservative. The pH is approximately 6.2 and the white crystalline
compound is only slightly soluble.
Mydriacyl is prepared in two strengths, .5% and 1%, and is pharmacologically
a parasympathicolytic or anticholinergic drug. Its action is unusual in that good
cycloplegia and mydriasis are obtainable in 20-25 minutes, and the effects of the
cycloplegia have worn off in 5-6 hours without use of a miotic.
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(e) antrenyl (oxyphenonium bromide)

OH

C

.C2H5
C

O

CH2—-CH2

N

C2H5

• Br

'CH
Antrenyl's chemical names: 2-diethylaminoethyl-alpha-phenyl-alpha-cyclo-hexylglycola.te methylbromide or diethyl (2-hydroxyethyl)methylammonium bromide-alphaphenyl-cyclohexaneglycolate.
Antrenyl is a potent synthetic anticholinergic quaternary ammonium compound
which is given in 5 mg. dose orally to relieve bronchospasm and reduce gastric
secretions and intestinal motility. It has been prepared as a 1% solution for investigative use in ophthalmology for cycloplegia of patients allergic to atropine. It is
prepared by Ciba and our chief interest is in its lack of allergic reactions. It is
used for preanesthetic medication, especially in the presence of atropine sensitivity.
(Also available in injectable solution in multiple dose vials as well as pediatric drops.)
B. Adrenergic Drugs (sympathomimetic) These drugs act on the effector cells
innervated by adrenergic nerves. A l l of these drugs must be used with care
in patients with hypertension.
I.

sympathetic stimulants — None of the following drugs should be used
in patients with narrow angles or shallow anterior chambers. Most of the
adrenergic compounds have similar structures and are called catecholamines
because the aromatic portion of the molecule is frequently catechol and
the aliphatic portion is usually an amine.
Catechol ( 1 , 2 dihydroxybenzene)

HO
a. epinephrine (adrenalin or 3, 4 dihydro-oxyphenylethanolmethylamine)

H
O
HO<^

^

CHCH2NHCH3

O
H
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Epinephrine (first hormone to be crystallized) can be prepared synthetically
but it is difficult to separate the less active dextro-form from the more active levoform. The levo-form occurs in the adrenal glands of animals and it is this source
from which most adrenalin in this country is obtained. However, there is 1-norepinephrine (levarterenol) also in the adrenal glands of animals. Most clinically
used epinephrine is contaminated with norepinephrine since the USP allows 4%
contamination. However, Parke Davis epinephrine (adrenalin) has only 0.1% contaminadon with 1-norepinephrine and is the most popular brand of adrenalin.
Epinephrine is a light brown, microcrystalline, odorless, light sensitive powder,
available as the hydrochloride in ampules of 1:1000 solution and in vials of 1:100
solution for inhalation, and 1:500 suspension in oil for intramuscular injection. The
bitartrate salt which contains only 55%- epinephrine is available (Suprarenin) in an
ampule containing 91 mg. of the powder and in a 1:1000 solution.
Epinephrine has many uses in medicine and for these, as well as side effects
and contraindications, the reader is referred to any standard text of pharmacology.
Ophthalmic

Preparations of

Epinephrine

(1) Local Anesthesia: Approximately one drop of 1:1000 adrenalin (Parke
Davis epinephrine) is placed in each cc. of local 2% or 4% xylocaine used for
infiltrative anesthesia. The ensuing local vasoconstriction prolongs the anesthesia.
(2) Decongestant: 1:1000 adrenalin is placed on each operative tray for hemostasis (constricts conjunctival vessels about the cornea) and for mydriasis (often
in combination with cocaine or cyclogyl).
(3) Open Angle Glaucoma Therapy: Topical epinephrine reduces aqueous
formation and improves outflow by an obscure mechanism. It may be a direct
action on the endothelial cells of the trabecular meshwork, the collagen or the
mucoids. It may be that epinephrine acts by secondary mechanical effects mediated
through the muscles of the ciliary body and iris, or secondary effects mediated through
nerves in the trabecular meshwork or even by vascular or secretory effects of epinephrine. Refrigeration is not required for stability of any of the topical epinephrines
used for open angle glaucoma therapy, but they deteriorate if left exposed to light.
(a)

Lyophrin:

Lyophrin is a 2% solution of 1-epinephrine bitartrate (Alcon Laboratories, Fort
Worth, Texas) and is a topically potent sympathomimetic amine. It is packaged
as sterile lyophilized crystals to be reconstituted when dispensed (100 mg. of powder
to 5 cc. of solution dispensed as Lyophrin diluent). The solution also contains
sodium bisulfite .2% and chlorobutanol (chloral derivative) .15% as preservatives.
Inactive ingredients include boric acid, disodium ethylenediaminetetracetate. Lyophrin
suppresses the secretion of aqueous, and the side effects include a slight burning or
irritation in the eyes. Lyophrin finds its greatest use either alone or as an adjunct
in the therapy of open angle glaucoma.
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(b)

Eppy:

Eppy is a 1 % solution of 1-epinephrine in a 7.5 cc. bottle of free base complex
of 1-epinephrine in a sterile ophthalmic vehicle (Barnes-Hind Laboratories, Incorporated, 895 Kifer Road, Sunnyvale, California). It has a pH of 7.4 and contains
sodium bisulfite .3% as a preservative and oxine sulfate . 0 1 % . The natural color
of Eppy is a pale yellow. The average dosage is two drops in each eye every 12
hours. There are no systemic effects noted, although occasional orbital pain is
complained of. The indications and contraindications for Eppy are the same as
Lyophrin and Glaucon.
(c)

Glaucon:

Glaucon is a 2% solution of l-epinephrine hydrochloride (Haug Drug Company,
Milwaukee 3, Wisconsin). The preparation also contains .02% benzalkonium chloride
and .2% sodium chloride and .3% sodium metabisulfite.
Glaucon has proved useful either alone or in combination with miotics and/or
carbonic anhydrase inhibitors in cases of open angie glaucoma that respond poorly
or not at all to other medications. There are no contraindications to the use of this
drug with the exception of narow angle glaucoma. Some patients with open angle
glaucoma will obtain a drop in the intraocular pressure within one hour. The minimal
dose is probably one drop a day, and the aqueous formation may be reduced by as
much as 30% using Glaucon.
(d) Epit rate:
Ayerst brand of l-epinephrine bitartrate prepared in 2% solution,
b. phenylephrine (Neo-synephrine)

H

o
CHCH2NHCH

o
V\
Neo-synephrine is a synthetic vasoconstrictor and mydriatic which is rarely used
in the therapy of glaucoma. Phenylephrine hydrochloride is manufactured by Winthrop
Laboratories, 1450 Broadway, New York 18, New York. It is used in ophthalmology
as a 10% solution in a 5 cc. bottle containing also sodium citrate, boric acid, dioctyl
sodium sulfosuccinate, chlorobutanol .4% and sodium bisulfite .2%. The onset of
action is more rapid than ephedrine, but less rapid than epinephrine, and the duration
of action is longer than epinephrine. It finds its greatest usefulness for mydriasis
of elderly patients but has the disadvantage of producing some epithelial stippling.
When applied following ophthaine, a marked superficial punctate keratitis ensues.
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Winthrop Laboratories also produces a viscous solution of 10% Neo-synephrine,
which contains sodium citrate, methylcellulose, sodium chloride, chlorobutanol, and
sodium bisulfite in 5 cc. bottles, and an emulsion of 10% phenylephrine hydrochloride
in 4 cc. bottles which contains liquid petrolatum, acacia, glycerin, ascorbic acid,
sodium benzoate, chlorobutanol, and sodium bisulfite.
c. levarterenol (1-norepinephrine, also levophcd)

H
O

Levophed is obtained from the adrenal medullae of cattle and is prepared as
the bitartrate available in 4 ml. ampules of 1:1000 (aqueous) solution.
Although rarely used in ophthalmology (most frequent use in intravenous therapy
for raising blood pressure in hypotensive states), it is stated to have similar effects
on the eye as l-epinephrine, consideration being made for different dosage requirements.
d. ephedrine (l-phenyl-2-methylamino-propanol)

HCHNHCHT

I
0CH3
Ephedrine occurs naturally as an alkaloid but is usually prepared synthetically.
It is available in capsules, elixer, syrup, and hypodermic tablets. Prepared for
ophthalmological use in a 3% solution as sulfate it has no cycloplegic action. Ephedrine
is not effecdve for mydriasis in the Negro.
e. amphetamine
dextro-amphetamine

(Benzedrine)
(Dexedrine)

CH3
Like ephedrine the amphetamines have many uses in medicine and having
mydriatic effects are useful in ophthalmology. They are prepared as the sulfate in
a 1% solution for this purpose. Benzedrine is usefid as a synergist with homatropine
and atropine, enhancing mydriasis but not cycloplegia.
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f. cocaine hydrochloride (benzoyl-methylecgonine)

H2C—CH

CH
H

H2C

CH

COOCH3
O

^

CH2

L

Installation of cocaine into the conjunctival sac in a 2-10% solution produces
slight to maximal mydriasis beginning within ten minutes, reaching its maximum
within 45 minutes and disappearing with 4 hours.
The mechanism of motor action is not known except it enhances the response
of sympathetically innervated structures to epinephrine probably by inhibiting the
action of amine oxidase.
Cocaine is obtained from the leaves of shrubs of the Erythroxylon family or
resynthesized from the base ecgonine obtained from the leaves.
Its effectiveness as a topical anesthetic is useful in surgery for conjunctival
anesthesia.
2. Adrenergic Blocking Agents (sympatholytic miotics)
a. dibenamirie ( N , N-dibenzyl-beta-chloroethylamine)

NCH2CH2CI

Dibenamine inhibits the response of the effector cells to epinephrine (and its
related compounds) and to sympathetic nervous impulses. It is administered intravenously because of its local ineffectiveness and irritation. The drug induces a
transitory miosis by relaxing the dilator fibers, dilates the conjunctival blood vessels,
may narrow the palpebral fissure and slightly lowers the intraocular pressure in normal
eyes. The usual dosage is 4-5 mg. per kg. a.nd a lowering of the intraocular pressure
occurs in 1-2 hours which usually remains for 24 hours. When used in ophthalmology
it is in the preoperative management of angle closure glaucoma.
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Dibenamine should not be used in the cardiac patient and it has produced atrial
fibrillation. This drug should not be used in the treatment of acute narrow ancle
glaucoma except just prior to surgery when all other measures have failed to reduce
intraocular pressure.
b. dihenzyline (phenoxybenzamine hydrochloride; N-(2-chloroethyl)N-(l-methyl-2-phenoxyethyl) benzylamine hydrochloride)

C6H5—O—CH2—CH —CH3
\

C6H5—CH-

N—CH.^—CH^

HCl

/

Dihenzyline hydrochloride (tertiary amine)
because it is locally less irritating.

has

largely replaced

dibenamine

Given systemically, dihenzyline blocks excitatory effects of adrenergic stimuli
on smooth muscle (miosis) and glands but does not alter the inhibitory responses
such as intestinal relaxation, bronchodilatalion and vasorelaxation. Side effects include
nasal congestion, miosis and orthostatic hypotension.
This drug is a coloriess crystalline compound, insoluble in water, soluble in
propylene glycol and available in capsules. Dihenzyline (Smith, Kline and French)
is supplied in 10 mg. oral tablets as well as the parenteral form.
Dosage is started with 30 mg. daily to 200 mg. maximum, and caution is used
with administration of this drug due to such side effects as hypotension with overdosage.
c. ergot alkaloids (ergotamine, ergocornine, ergochristine and ergocryptine)
and the hydrogenated ergot alkaloids (dihydroergotamine, etc.)
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Used by subcutaneous injection of .25 to .5mg. in I % solution ergot alkaloids
lower the intraocular pressure in 80-90% of simple glaucoma cases. For the most
part, however, they have been abandoned for their unpredictable effects.
II. Miscellaneous

Drugs

A. pyrimethamine (Daraprim; 2, 4-diamino-5(p-chlorophenyl) -6-cthylpyrimidine)

,NH2

CH2CH3
A recent addition (1951-1952) to the synthetic antimalarials, Daraprim has
been used (without clear-cut success) in the therapy of the protozoae. Toxoplasma
gondii.
Toxic effects are primarily registered in the bone marrow were antifolinic acid
properties produce a megaloblastic anemia and suppression of bone marrow elements,
including platelets.
Management

of the Patient taking

Daraprim:

1. Daraprim dosage: There is no general agreement of what constitutes adequate
Daraprim therapy in acute toxoplasmosis uveitis. A loading dose of 75-100
mg. (supplied in 25 mg. oral tablets) twice a day for 2 days, and then 25 mg.
twice a day thereafter for 2-3 months is average. Then the patient may take
25 mg. daily for several months.
2. Addhional therapy: Cortisone is frequently used to diminish the inflammatory
reaction produced by the live as well as dead organism. A dosage of prednisone
10-15 mg. four times daily for a week followed by mg. four times daily for
4-6 weeks may be required or desired. The drug is then gradually tapered to
discontinuance.
Sulfa enhances the effect of Daraprim and is given as terfonyl 2 gms.
immediately and then 1 gm. four times a day, continued for several weeks to
several months. The more potent Kynex may be substituted for triple sulfa
(smaller dosage required to sustain blood levels).
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Spiramycin has been advocated also as having an additive effect against
toxoplasma when used with Daraprim. It is given in 250 mg. dosage four
times a day and continued 4-6 weeks.
3. Precautions of therapy:
a. When using cortisone a negative history for duodenal ulcer and tuberculosis must be obtained. A negative chest x-ray report should be obtained.
b. Because of the danger of a megaloblastic anemia, a platelet count, white
blood cell count, and hemoglobin are obtained once a week and preferably twice a week.
c. I f a leukopenia is present (less than 3,000 cu. mm.) or the platelet
count is less than 80,000 cu. mm. Daraprim must be discontinued at
least temporarily. Leucovorin (fohnic acid) may be given parenterally
5 mg. twice a day to hasten the return of a normal blood count. Patients
may eat a yeast cake once or twice a day prophylactically. The folinic
acid dosage is calculated at about one-fifth the Daraprim dosage.
d. A weekly urinalysis is obtained to rule out complications of sulfa therapy,
i.e., crystalluria.
B. urea (Carbamide) i.e., diamide of carbonic acid.

H2N

CO

NH2

When Diamox and miotics have failed, urea intravenously is most valuable for
lowering the intraocular pressure of acute angle closure glaucoma. The mechanism
of action appears to be an osmotic influence on the blood-aqueous barrier. Oral
urea was used as a diuretic as early as 1852. Intravenous urea is usually reserved
for those cases unresponsive to other therapy or for lowering intraocular pressure
just prior to surgery.
Urea for injection (Ureaphil. Abbod) is supplied as an anhydrous lyophilized,
sterile powder. It is packaged in units containing 40 gms. of pyrogen-free urea in a
250 ml. botde.
The solution is prepared as 30% urea with total urea calculated at 1.0-1.5 gms.
per kg. of the patient's body weight. (Example: 80 gms. in 210 mis. = 30%
solution) The diluent may be 5 or 10% glucose in water (dextrose or invert sugar)
and the solution is prepared fresh for each case (ammonia develops in the solution
with prolonged standing). It is administered no faster than 60 gtts/minute. The
patient's oral fluid intake should be restricted despite his extreme thirst or the desired
osmotic effect will not be achieved.
In the presence of liver or kidney disease, urea should be administered with
caution. In the adult a total dose should not exceed 120 gms. (In children, the dose
is based on weight.) The dosage must, to some extent, be individualized to the
217

"T

TUCKER
patient in order to prevent disorientation, circulatory collapse, etc. Inasmuch as the
blood volume is markedly increased, this drug should not be used in patients with
congestive heart failure.
Intraocular pressure will usually fall after l.V. urea in 20-30 minutes and remain
down for 4-10 hours.
Marked diuresis is produced and patients going to surgery should, perhaps, have
a Foley catheter inserted. Its diuretic effect is produced by the osmotic effect in
the renal tubules lessening re-absorption of water. There are many other medical
uses of intravenous urea which are not related to this paper, and the reader is
referred to the literature.
Urevert is another l.V. urea preparation (Travcnol Laboratories, Inc., Division
of Baxter Laboratories, Inc., Morton Grove, III.) supplied as a 30% synthetic urea
lyophilized powder with 10%* invert sugar in a kit for simple mixing. Two sizes are
available, 40 gms. and 90 gms. of urea per vial.
C. carbonic anhydrase

inhibitors

The following four drugs are used either in the therapy of acute angle closure
glaucoma or in difficult to control open angle glaucoma cases. The first of these
drugs available was Diamox (acetazolamide) in the mid 1950's. It and the other
drugs in the group (all are sulfonamides with substitutions at the benzene ring that
characterizes the sulfonamides used as chemotherapeutic agents) were introduced as
diuretics but all are now used for non-diuretic purposes. Because they are sulfonamide
derivatives, it is possible for the reactions to occur which have been described for
the bacteriostatic sulfonamides. These include crystalluria, renal calculus, leukopenia,
rashes, hemolytic anemia, and bone marrow depression.
sulfanilamide

o
•NH2
O
1. acetazolamide (Diamox) Lederle Laboratories,
Division of American Cyanamid Co., Pearl River, N . Y.
2-acetylamino-l, 3, 4-thiadiazole-5-sulfonamide

H

CH-^

N

N

I II

C

—N

II
O

Ll^ J }
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Diamox dosage orally varies from 125 mg. every 12 hours to 500 mg. every
4 hours, or in the case of an acute angle closure glaucoma 500 mg. intravenously.
The most commonly used oral dose is 250 mg. every 6 hours, and this is decreased
by patient intolerance or increased by patient need. More recently a sustained release
capsule by Lederie containing 500 mg. of Diamox for 12 hour release has been
made available. Each vial of Diamox parenteral contains 500 mg. of acetazolamide
sodium and sodium hydroxide to pH 9.2. The solution should be reconstituted with
at least 5 cc. of sterile distilled water (10 cc. very satisfactory) and intravenous
route of injection is preferable although it can be given intramuscularly (one may
give Vi dose l.V. and V2 dose I . M . ) .
Diamox will decrease production of aqueous and effect a lowering of intraocular
pressure in Vi to 3 hours and this effect lasts up to 6 hours, whereas Neptazane
will not effect a lower perssure for 6-8 hours but will sustain its effect 8-10 hours.
Intravenous Diamox will produce lowering of intraocular pressure in a few minutes
that reaches its lowest level in Vi - 4 hours.
There are other medical uses of Diamox not within the scope of this presentation
and are therefore omitted. Side effects of Diamox include drowsiness, paresthesias,
nausea, vomiting, etc. Conlraindications include idiopathetic hyperchloremic acidosis
and known states of sodium or potassium depletion.

2.

methazolamide (Neptazane)

Lederle

5-acetylamino-4 methyl-A^-L 3, 4,-thiadiazoline-2-sulfonamide
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Neptazane will decrease intraocular pressure with Vi the dose of Diamox and
it is reported that 50% of patients unable to tolerate the side effects of Diamox take
Neptazane without difficulty. Also, 50% of those patients whose intraocular pressure
failed to respond to Diamox reportedly responded to Neptazane. Effective dosage
is 50-100 mg. 2 or 3 times a day. Neptazane is prepared only as a 50 mg. oral
tablet. The pressure reaches its lowest level in 6-8 hours and is maintained at this
level 8-10 hours. If tolerated, Diamox is the drug of choice.
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3. etho.xyzoleamide (Cardrase) Upjohn Co., Kalamazoo 99, Michigan

N
C2H5O—

SO2NH2

Cardrase is a similar drug to Diamox (carbonic anhydrase
supplied as an oral tablet in 62.5 and 125 mg. sizes.

inhibitor).

It is

The recommended dose is 62.5 to 125 mg. twice to four times a day; intermittent
rather than continuous therapy in primary and secondary glaucomas because of the
possibility of electrolyte imbalances being produced. For best results miotics are
used with Cardrase. The same side effects and contraindications apply for Cardrase
as are listed for Diamox.
4. dichlorphenamide (Daranide, Oratrol) Merck, Sharp & Dohme
1, 3-disulfamyl-4, 5-dichlorobenzene
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Daranide is another carbonic anhydrase inhibitor that may successfully be substituted for Diamox in the patient who experiences intolerable side effects from Diamox
in glaucoma therapy.
The dosage varies from 50-200 mg. every 6-8 hours. (A priming dose of 100-200
mg. is given at the start of therapy.) It is said to produce less metabolic acidosis
but may induce a more pronounced renal loss of potassium. It is supplied only in
50 mg. tablets for oral administration.
Daranide has been noted to be more effective when combined with a cholinesterase
inhibitor in glaucoma therapy.
Side effects and contraindications are identical with those listed for Diamox.
Short-term therapy is recommended.
220

OPHTHALMOLOGICALLY
D.

IMPORTANT

DRUGS

glycerol

H

I
H—C—OH

I

H—C—OH

I
H—C — O H
H
At the present time the most convenient hypertonic agent is 1, 2, 3-propanetriol
or "glycerol". Of the hypertonic agents currendy in vogue, urea has the disadvantage
of being poorly tolerated orally — usually making the nausea and vomiting of already
sick, acute glaucoma patients worse — and when given intravenously has the definite
risk of causing a slough if the l.V. infiltrates. Glycerol is used orally, a 50%
solution made up in normal saline or water and flavored with a citrus fruit extract,
makes a passably palatable cocktail. 1-2 gm. per kg. of body weight is an appropriate
dose which will drop intraocular pressure dramatically within about 40 minutes. A
handy rule of thumb is to use 1.50 cc. per pound of a 50% "cocktail".
E.

ethylenediamine acetic acid (EDTA or Versene)
EDTA belongs to a class of chemical agents known as chelate compounds

or chelating agents. Such compounds will inactivate a metallic ion with the formation
of an inner ring structure in the molecule, the metallic ion becoming a member of

HOOC-CH2 ^

CH2-COOH
N—CH,—CH,—N

HOOC—CH2

/

\

CH,—COOH

Versene
the ring. Thus is formed a stable soluble complex with calcium ions and certain
heavy metals.
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Calcium Versenate
In ophthalmology it is practical to remove the calcium from corneal tissue in
band keratopathy by chelation. The calcium deposit most frequently lies between
the epithelium and Bowman's membrane, and after removal of the corneal epithelium
the calcium deposit is vulnerable.
A .01 molar solution is used and the cornea is irrigated with 100 cc. for 15
minutes by placing a corneal irrigation cup over the cornea and removing the EDTA
with a suction bulb to replace fresh Versenate. (Solutions up to a concentration
of .05 molar may be used in the cup.)
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